MOTS-c

Overview

Mitochondrial-derived peptide that regulates metabolic homeostasis and insulin sensitivity.

Reported benefits

Enhanced metabolism, improved insulin sensitivity, increased exercise capacity, longevity benefits

Protocols & dosing

Typical dosage: 5-10 mg (weekly).

Detailed dosing protocols have not yet been catalogued.

FDA & legal status

MOTS-c is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed MOTS-c from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place MOTS-c on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 1 — July 23, 2026. PCAC agenda: BPC-157, KPV, TB-500, MOTS-c. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

Vendor information

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Side effects & safety

Reported side effects: Well-tolerated. Minimal reported side effects

References

No external sources have been catalogued for this article yet.